CSL Behring, King of Prussia, PA, USA.
Immune Deficiency Foundation, Towson, MD, USA.
BMC Immunol. 2020 Aug 10;21(1):47. doi: 10.1186/s12865-020-00371-y.
Subcutaneous immunoglobulin (SCIG) is increasingly utilized in primary immunodeficiency (PI). Understanding factors associated with treatment experience and satisfaction can optimize patient outcomes. We analyzed Immune Deficiency Foundation (IDF) survey data to evaluate patient-reported outcomes (PROs) in relation to SCIG training and infusion characteristics. Respondents' PRO scores were rank ordered into 'best', 'intermediate', and 'worst' tertiles. Predicted probabilities of being in the best tertile with any combination of characteristics were generated for each PRO.
In 366 SCIG respondents, higher odds of being in the best PRO tertile were driven by favorable training characteristics (particularly, higher confidence post-training and no training barriers) and efficient infusions (infusion preparation ≤20 min and actual infusion < 2 h). Age (≤17 years old) and treatment experience (> 2 years) increased the odds of being in the best tertiles. Compared with the least favorable training/infusion characteristics, those with the most favorable training/infusion characteristics had higher predicted probabilities of being in the best tertiles: TSQM side effects, 59% vs 4%; convenience, 52% vs 4%; effectiveness, 27% vs 13%; global, 26% vs 3%; PROMIS Fatigue, 44% vs 18%.
Increased experience with SCIG consistently improved PROs, but our findings predicted that enhanced training and infusion characteristics improve patient treatment satisfaction beyond that achieved by experience alone.
皮下免疫球蛋白(SCIG)在原发性免疫缺陷(PI)中的应用越来越多。了解与治疗经验和满意度相关的因素可以优化患者的治疗效果。我们分析了免疫缺陷基金会(IDF)的调查数据,以评估与 SCIG 培训和输注特征相关的患者报告结局(PRO)。将受访者的 PRO 评分按“最佳”、“中等”和“最差”三分位进行排序。针对每种 PRO,生成了具有任何组合特征的处于最佳三分位的预测概率。
在 366 名 SCIG 受访者中,较高的 PRO 最佳三分位几率与有利的培训特征(尤其是培训后信心较高且无培训障碍)和高效的输注(输注准备时间≤20 分钟且实际输注时间<2 小时)有关。年龄(≤17 岁)和治疗经验(>2 年)增加了处于最佳三分位的几率。与最不利的培训/输注特征相比,具有最有利的培训/输注特征的患者处于最佳三分位的预测概率更高:TSQM 副作用为 59%比 4%;便利性为 52%比 4%;有效性为 27%比 13%;总体为 26%比 3%;PROMIS 疲劳为 44%比 18%。
随着 SCIG 经验的增加,PRO 持续改善,但我们的研究结果表明,增强培训和输注特征可以提高患者的治疗满意度,超出仅通过经验实现的满意度。